LIMINATUS PHARMA INC

Company Overview

Liminatus Pharma Inc (ticker LIMN) is a pre‑clinical biotechnology company in the Healthcare sector focused on advancing its pipeline (notably program IBA101) and building out public‑company operations following a business combination that closed April 30, 2025. The company has no product revenues, an accumulated deficit (~$28.9M), and recently completed a PIPE financing and Nasdaq listing while terminating certain legacy TDT license agreements. Key balance‑sheet events include conversion of related‑party debt (~$14.8M) into equity, assumption of Iris liabilities (~$10.7M), recognition (and subsequent settlement) of deferred underwriting fees, and continued cash burn with management disclosing substantial doubt about going‑concern status within one year.

Executive Compensation Practices

As a pre‑revenue Biotechnology company in the Healthcare sector, executive pay is likely to be heavily equity‑based (stock awards, options, restricted stock) with modest cash salaries to conserve liquidity; compensation design will emphasize retention and alignment with long‑term R&D and financing milestones. Company‑specific drivers include successful capital raises (PIPE and future financings), advancing IBA101 through preclinical/clinical milestones, and controlling G&A spend after costs spiked for public‑company readiness — any single‑event payments tied to the business combination or underwriting fees may have temporarily influenced pay disclosures. Expect the board to lean on equity grants or milestone bonuses to manage cash constraints, and to revisit pay packages after near‑term financing or clinical progress reduces dilution risk.

Insider Trading Considerations

Insiders at early‑stage biotech firms like Liminatus typically trade around discrete events — financings, registration/listing milestones, clinical readouts, and lock‑up expirations — and this company’s recent PIPE, debt‑to‑equity conversions, and Nasdaq listing create several obvious windows for material insider activity. The conversion of related‑party debt into equity substantially changed insider holdings and may lead to future stock sales once any contractual lock‑ups or resale restrictions lift; conversely, insider purchases are less likely while executives have limited cash and the company is cash‑constrained. Regulatory considerations include Section 16 reporting, potential increased SEC scrutiny of related‑party transactions, customary blackout periods around material announcements, and the advisability of 10b5‑1 plans — monitor Form 4 filings and prospectus/10‑Q disclosures for large conversions, secondary sales, or option exercises that could move the stock.